Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1
Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disease involving the skin and central nervous system (CNS), and also characterized by skeletal and spinal schwannomas that may cause chronic neurogenic pain. Furthermore, pain in NF1 is underestimated, even though it has an impact on quali...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2021-05-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/2424 |
| _version_ | 1819047451591442432 |
|---|---|
| author | Eleonora Virgilio Domizia Vecchio Paola Naldi Roberto Cantello |
| author_facet | Eleonora Virgilio Domizia Vecchio Paola Naldi Roberto Cantello |
| author_sort | Eleonora Virgilio |
| collection | DOAJ |
| description | Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disease involving the skin and central nervous system (CNS), and also characterized by skeletal and spinal schwannomas that may cause chronic neurogenic pain. Furthermore, pain in NF1 is underestimated, even though it has an impact on quality of life. Multiple sclerosis (MS) is the most common acquired demyelinating disease that may in later stages present with refractory spasticity, particularly in the lower limbs. Oromucosal cannabinoid sprays are currently available for spasticity treatment in MS, with encouraging results on MS pain, but few data have been reported regarding the use of cannabinoids in NF1. We report the successful treatment of chronic neurogenic pain and spasticity in a patient with co-occurrence of NF1 and MS after a poor response to standard approaches. |
| first_indexed | 2024-12-21T11:00:34Z |
| format | Article |
| id | doaj.art-d6db65cea95948f6b566d6e35091ad12 |
| institution | Directory Open Access Journal |
| issn | 2284-2594 |
| language | English |
| last_indexed | 2024-12-21T11:00:34Z |
| publishDate | 2021-05-01 |
| publisher | SMC MEDIA SRL |
| record_format | Article |
| series | European Journal of Case Reports in Internal Medicine |
| spelling | doaj.art-d6db65cea95948f6b566d6e35091ad122022-12-21T19:06:22ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-05-0110.12890/2021_0024242040Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1Eleonora Virgilio0Domizia Vecchio1Paola Naldi2Roberto Cantello3Neurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, ItalyNeurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, ItalyNeurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, ItalyNeurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, ItalyNeurofibromatosis type 1 (NF1) is a rare autosomal dominant disease involving the skin and central nervous system (CNS), and also characterized by skeletal and spinal schwannomas that may cause chronic neurogenic pain. Furthermore, pain in NF1 is underestimated, even though it has an impact on quality of life. Multiple sclerosis (MS) is the most common acquired demyelinating disease that may in later stages present with refractory spasticity, particularly in the lower limbs. Oromucosal cannabinoid sprays are currently available for spasticity treatment in MS, with encouraging results on MS pain, but few data have been reported regarding the use of cannabinoids in NF1. We report the successful treatment of chronic neurogenic pain and spasticity in a patient with co-occurrence of NF1 and MS after a poor response to standard approaches.https://www.ejcrim.com/index.php/EJCRIM/article/view/2424multiple sclerosisneurofibromatosis type 1spasticitychronic paincannabinoids |
| spellingShingle | Eleonora Virgilio Domizia Vecchio Paola Naldi Roberto Cantello Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1 European Journal of Case Reports in Internal Medicine multiple sclerosis neurofibromatosis type 1 spasticity chronic pain cannabinoids |
| title | Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1 |
| title_full | Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1 |
| title_fullStr | Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1 |
| title_full_unstemmed | Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1 |
| title_short | Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1 |
| title_sort | efficacy of cannabinoids on spasticity and chronic pain in a patient with co occurrence of multiple sclerosis and neurofibromatosis type 1 |
| topic | multiple sclerosis neurofibromatosis type 1 spasticity chronic pain cannabinoids |
| url | https://www.ejcrim.com/index.php/EJCRIM/article/view/2424 |
| work_keys_str_mv | AT eleonoravirgilio efficacyofcannabinoidsonspasticityandchronicpaininapatientwithcooccurrenceofmultiplesclerosisandneurofibromatosistype1 AT domiziavecchio efficacyofcannabinoidsonspasticityandchronicpaininapatientwithcooccurrenceofmultiplesclerosisandneurofibromatosistype1 AT paolanaldi efficacyofcannabinoidsonspasticityandchronicpaininapatientwithcooccurrenceofmultiplesclerosisandneurofibromatosistype1 AT robertocantello efficacyofcannabinoidsonspasticityandchronicpaininapatientwithcooccurrenceofmultiplesclerosisandneurofibromatosistype1 |